Having a Primary Care Provider and Receipt of Recommended Preventive Care Among Men in New York City.
Am J Mens Health. 2010 Aug 26;
Authors: Jasek JP
To assess the role of having a primary care provider (PCP) in men’s up-to-date receipt of recommended preventive services (colonoscopy, pneumococcal and seasonal influenza vaccination, cholesterol and blood pressure screenings), data from the 2005 and 2006 New York City Community Health Surveys (N = 3,728 [2006], 2,810 [2005]) were analyzed. PCP prevalence and men’s uptake of each service, overall and by age, race/ethnicity, education, income, insurance status, marital status, and nativity, were evaluated. After controlling for insurance status and other factors, having a PCP significantly predicted receipt of each service (adjusted prevalence ratio from 1.12 [1.08, 1.16] to 1.72 [1.35, 2.22]) and total services. Colonoscopy and seasonal influenza and pneumococcal vaccination receipt were below 70% with or without a PCP. Efforts to increase the proportion of men having a PCP are needed to improve receipt of recommended services. Maximizing awareness and provision of low-use preventive services may be useful.
20798146
– Having a Primary Care Provider and Receipt of Recommended Preventive Care Among Men in New York City.
Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates.
Curr Pharm Des. 2010 Aug 20;
Authors: Buijs JT, Kuijpers CC, van der Pluijm G
Cancer is a major leading cause of death in the western world (following heart diseases). It poses an enormous burden on patients and society with a major impact on healthcare and economy. Once cancers have spread to the skeleton, treatment options are predominantly limited to palliation, treatment of hypercalcemia and prevention of pathological fractures. Despite the elaborate efforts of modern medicine to improve treatment, novel therapies for the treatment of solid tumors in patients with advanced disease, including metastatic bone disease, have generally failed to improve patient overall survival. Despite initial beneficial responses on metastatic tumor burden this is frequently followed by re-growth of therapy resistant, malignant metastatic bone lesions. Cancer relapse in bone coincides with devastating consequences and causes considerable morbidity. Bisphosphonates represent the current gold standard in bone metastasis therapies. Because of the progress made in our understanding of the pathogenesis of skeletal metastasis using preclinical models, newer and more efficacious compounds and therapies have been developed that are being evaluated (or will soon be) in clinical trails. In this chapter, we discuss novel therapeutic targets and strategies for the treatment of metastatic bone disease. Future, successful treatment of skeletal metastasis will rely on targeting critical molecular mediators/processes in both metastasis-initiating subpopulations of osteotropic cancers (“the seed”) together with their supportive, cellular and extra-cellular surrounding bone/bone marrow stroma (“the soil”).
20722621
– Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates.
Venous thromboembolism in medical patients treated in the setting of primary care: A nationwide case-control study in Italy.
Thromb Res. 2010 Aug 13;
Authors: Cimminiello C, Filippi A, Mazzaglia G, Pecchioli S, Arpaia G, Cricelli C
OBJECTIVES: The risk of venous thrombotic events (VTE) among medical outpatients is still not clear and it remains to be clarified whether medical diseases involve the same risk if managed at home or in hospital. The aim of this study was to evaluate in the setting of outpatient family medicine the relationship between VTE and medical conditions known to be at risk during a hospital stay. DESIGN AND SETTING: The study involved a nationwide retrospective observation according to a nested case-control method; 400 general practitioners throughout Italy constituted the network for data collection. Between 2001 and 2004, all cases recorded as having VTE were entered; ten control patients without VTE, matched by sex, physician, and age, were selected from the database for each case. RESULTS: The eligible population comprised 372,000 patients and 1,624 incident VTE were recorded. Univariate analysis indicated hospitalization (OR 5.02; 95% CI 4.01-6.29), cancer (OR 3.06; 95% CI 2.47-3.79), acute infectious disease (OR 2.93; 95% CI 1.94-4.43), neurological disease (OR 2.60; 95% CI 1.56-4.33), congestive heart failure (CHF) (OR 2.48; 95% CI 1.68-3.69), paralysis (OR 1.87; 95% CI 1.51-2.32), COPD (OR 1.58; 95% CI 1.29-1.95), stroke (OR 1.62; 95% CI 1.24-2.12), superficial venous thrombosis (OR 1.51; 95% CI 1.11-2.04, and rheumatic diseases (OR 1.49; 95% CI 1.28-1.74) as significantly associated with an increased risk for VTE. After adjustment, only transient or definitive paralysis, cancer, acute infectious disease, congestive heart failure, neurological diseases, and previous hospitalization remained associated. CONCLUSIONS: This large study indicates that VTE outpatients seen by general practitioners in Italy have a high prevalence of the same medical diseases associated with VTE among patients treated in hospital.
20709364
– Venous thromboembolism in medical patients treated in the setting of primary care: A nationwide case-control study in Italy.
